367 related articles for article (PubMed ID: 11872682)
1. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes.
Mayerson AB; Hundal RS; Dufour S; Lebon V; Befroy D; Cline GW; Enocksson S; Inzucchi SE; Shulman GI; Petersen KF
Diabetes; 2002 Mar; 51(3):797-802. PubMed ID: 11872682
[TBL] [Abstract][Full Text] [Related]
2. Thiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability.
Oakes ND; Thalén PG; Jacinto SM; Ljung B
Diabetes; 2001 May; 50(5):1158-65. PubMed ID: 11334421
[TBL] [Abstract][Full Text] [Related]
3. Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses.
Juurinen L; Kotronen A; Granér M; Yki-Järvinen H
J Clin Endocrinol Metab; 2008 Jan; 93(1):118-24. PubMed ID: 17956948
[TBL] [Abstract][Full Text] [Related]
4. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected].
Carey DG; Cowin GJ; Galloway GJ; Jones NP; Richards JC; Biswas N; Doddrell DM
Obes Res; 2002 Oct; 10(10):1008-15. PubMed ID: 12376581
[TBL] [Abstract][Full Text] [Related]
5. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes.
Petersen KF; Dufour S; Befroy D; Garcia R; Shulman GI
N Engl J Med; 2004 Feb; 350(7):664-71. PubMed ID: 14960743
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice.
Kim JK; Fillmore JJ; Gavrilova O; Chao L; Higashimori T; Choi H; Kim HJ; Yu C; Chen Y; Qu X; Haluzik M; Reitman ML; Shulman GI
Diabetes; 2003 Jun; 52(6):1311-8. PubMed ID: 12765938
[TBL] [Abstract][Full Text] [Related]
7. Effects of rosiglitazone on abnormal lipid kinetics in HIV-associated dyslipidemic lipodystrophy: a stable isotope study.
Sekhar RV; Patel SG; D'Amico S; Shi J; Balasubramanyam A; Rehman K; Jahoor F; Visnegarwala F
Metabolism; 2011 Jun; 60(6):754-60. PubMed ID: 20832829
[TBL] [Abstract][Full Text] [Related]
8. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.
Bajaj M; Suraamornkul S; Pratipanawatr T; Hardies LJ; Pratipanawatr W; Glass L; Cersosimo E; Miyazaki Y; DeFronzo RA
Diabetes; 2003 Jun; 52(6):1364-70. PubMed ID: 12765945
[TBL] [Abstract][Full Text] [Related]
9. Reduction of intramyocellular lipid following short-term rosiglitazone treatment in Zucker fatty rats: an in vivo nuclear magnetic resonance study.
Jucker BM; Schaeffer TR; Haimbach RE; Mayer ME; Ohlstein DH; Smith SA; Cobitz AR; Sarkar SK
Metabolism; 2003 Feb; 52(2):218-25. PubMed ID: 12601636
[TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone improves muscle insulin sensitivity, irrespective of increased triglyceride content, in ob/ob mice.
Muurling M; Mensink RP; Pijl H; Romijn JA; Havekes LM; Voshol PJ
Metabolism; 2003 Aug; 52(8):1078-83. PubMed ID: 12898477
[TBL] [Abstract][Full Text] [Related]
11. Short-term administration of isotretinoin elevates plasma triglyceride concentrations without affecting insulin sensitivity in healthy humans.
Stoll D; Binnert C; Mooser V; Tappy L
Metabolism; 2004 Jan; 53(1):4-10. PubMed ID: 14681834
[TBL] [Abstract][Full Text] [Related]
12. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat.
Oakes ND; Kennedy CJ; Jenkins AB; Laybutt DR; Chisholm DJ; Kraegen EW
Diabetes; 1994 Oct; 43(10):1203-10. PubMed ID: 7926289
[TBL] [Abstract][Full Text] [Related]
13. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.
Miyazaki Y; Mahankali A; Matsuda M; Glass L; Mahankali S; Ferrannini E; Cusi K; Mandarino LJ; DeFronzo RA
Diabetes Care; 2001 Apr; 24(4):710-9. PubMed ID: 11315836
[TBL] [Abstract][Full Text] [Related]
14. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes.
Hällsten K; Virtanen KA; Lönnqvist F; Sipilä H; Oksanen A; Viljanen T; Rönnemaa T; Viikari J; Knuuti J; Nuutila P
Diabetes; 2002 Dec; 51(12):3479-85. PubMed ID: 12453903
[TBL] [Abstract][Full Text] [Related]
15. Insulin and rosiglitazone regulation of lipolysis and lipogenesis in human adipose tissue in vitro.
McTernan PG; Harte AL; Anderson LA; Green A; Smith SA; Holder JC; Barnett AH; Eggo MC; Kumar S
Diabetes; 2002 May; 51(5):1493-8. PubMed ID: 11978647
[TBL] [Abstract][Full Text] [Related]
16. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.
Miyazaki Y; He H; Mandarino LJ; DeFronzo RA
Diabetes; 2003 Aug; 52(8):1943-50. PubMed ID: 12882909
[TBL] [Abstract][Full Text] [Related]
17. Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats.
Kramer D; Shapiro R; Adler A; Bush E; Rondinone CM
Metabolism; 2001 Nov; 50(11):1294-300. PubMed ID: 11699047
[TBL] [Abstract][Full Text] [Related]
18. Thiazolidinediones enhance insulin-mediated suppression of fatty acid flux in type 2 diabetes mellitus.
Racette SB; Davis AO; McGill JB; Klein S
Metabolism; 2002 Feb; 51(2):169-74. PubMed ID: 11833043
[TBL] [Abstract][Full Text] [Related]
19. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.
Bajaj M; Suraamornkul S; Piper P; Hardies LJ; Glass L; Cersosimo E; Pratipanawatr T; Miyazaki Y; DeFronzo RA
J Clin Endocrinol Metab; 2004 Jan; 89(1):200-6. PubMed ID: 14715850
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects.
Virtanen KA; Hällsten K; Parkkola R; Janatuinen T; Lönnqvist F; Viljanen T; Rönnemaa T; Knuuti J; Huupponen R; Lönnroth P; Nuutila P
Diabetes; 2003 Feb; 52(2):283-90. PubMed ID: 12540598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
